$CLCS
Cell Source, Inc. Stock $clcs

$clcs Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224024903 Filed on June 24, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$373.7K	$507.0K	$2.605M
YoY Change	-30.8%	-16.56%	19.53%
% of Gross Profit
Research & Development	$820.0K	$359.4K	$1.578M
YoY Change	121.62%	-22.73%	-18.58%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.194M	$866.4K	$4.325M
YoY Change	31.83%	-19.24%	3.59%
Operating Profit	-$1.194M		-$4.325M
YoY Change	31.83%		3.59%
Interest Expense	-$295.1K	-$40.95K	-$1.038M
YoY Change	-22.34%	-84.52%	4.57%
% of Operating Profit
Other Income/Expense, Net	-$295.1K		-$995.9K
YoY Change	-12.21%		0.35%
Pretax Income	-$1.489M	-$1.050M	-$5.321M
YoY Change	20.06%	-21.49%	2.97%
Income Tax
% Of Pretax Income
Net Earnings	-$1.489M	-$1.371M	-$5.321M
YoY Change	19.91%	-15.63%	2.96%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04		-$0.17
Diluted Earnings Per Share	-$0.04	-$0.04	-$0.17
COMMON SHARES
Basic Shares Outstanding	41.02M shares	38.55M shares	37.79M shares
Diluted Shares Outstanding	41.02M shares		37.79M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.55K	$22.20K	$22.20K
YoY Change	352.75%	-90.03%	-90.03%
Cash & Equivalents	$90.55K	$22.20K
Short-Term Investments
Other Short-Term Assets	$17.72K	$12.22K	$173.0K
YoY Change	8.46%	-46.89%	-7.6%
Inventory
Prepaid Expenses	$321.5K	$160.8K
Receivables
Other Receivables
Total Short-Term Assets	$429.8K	$195.2K	$195.2K
YoY Change	19.38%	-52.38%	-52.38%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	-$3.00	$1.00	$0.00
YoY Change	-100.13%	-120.0%
TOTAL ASSETS
Total Short-Term Assets	$429.8K	$195.2K	$195.2K
Total Long-Term Assets	-$3.00	$1.00	$0.00
Total Assets	$429.8K	$195.2K	$195.2K
YoY Change	18.61%	-52.38%	-52.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.752M	$1.467M	$1.467M
YoY Change	88.82%	115.64%	115.64%
Accrued Expenses	$5.364M	$4.750M	$4.750M
YoY Change	22.74%	219.68%	12.58%
Deferred Revenue
YoY Change
Short-Term Debt	$889.2K	$710.3K	$710.3K
YoY Change	30.77%	-7.53%	-7.53%
Long-Term Debt Due	$1.313M	$1.229M	$1.229M
YoY Change	-27.08%	16.11%	16.11%
Total Short-Term Liabilities	$17.75M	$15.81M	$15.81M
YoY Change	15.93%	21.18%	21.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.75M	$15.81M	$15.81M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$17.75M	$15.81M	$15.81M
YoY Change	15.95%	21.18%	21.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.43M	-$41.67M
YoY Change	13.12%	14.64%
Common Stock	$41.94K	$39.83K
YoY Change	9.9%	10.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$17.32M	-$15.61M	-$15.61M
YoY Change
Total Liabilities & Shareholders Equity	$429.8K	$195.2K	$195.2K
YoY Change	18.61%	-52.38%	-52.38%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.489M	-$1.371M	-$5.321M
YoY Change	19.91%	-15.63%	2.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.123M	-$717.9K	-$2.348M
YoY Change	7.98%	-0.75%	-25.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.214M	737.4K	$2.147M
YoY Change	31.9%	-16.2%	-34.29%
NET CHANGE
Cash From Operating Activities	-1.123M	-717.9K	-$2.348M
Cash From Investing Activities
Cash From Financing Activities	1.214M	737.4K	$2.147M
Net Change In Cash	90.52K	19.54K	-$200.5K
YoY Change	-175.43%	-87.53%	-254.71%
FREE CASH FLOW
Cash From Operating Activities	-$1.123M	-$717.9K	-$2.348M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	CLCS	Financing Of Directors And Officers Insurance FinancingOfDirectorsAndOfficersInsurance		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001569340
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	CLCS	Loss On Legal Settlement LossOnLegalSettlement		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	CLCS	Proceeds From Issuance Of Convertible Preferred Stock And Warrants Net ProceedsFromIssuanceOfConvertiblePreferredStockAndWarrantsNet		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	CLCS	Conversion Of Series C Convertible Preferred Stock Into Common Stock ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock		usd
CY2022	CLCS	Conversion Of Accrued Expenses Into Note Principal ConversionOfAccruedExpensesIntoNotePrincipal		usd
CY2022	CLCS	Accrual Of Warrant Obligations In Connection With Issuance Of Notes Payable AccrualOfWarrantObligationsInConnectionWithIssuanceOfNotesPayable		usd
CY2022	CLCS	Warrants Issued In Satisfaction Of Accrued Warrant Obligation WarrantsIssuedInSatisfactionOfAccruedWarrantObligation		usd
CY2023	CLCS	Issuance Of Warrants In Satisfaction Of Accrued Interest IssuanceOfWarrantsInSatisfactionOfAccruedInterest		usd
CY2022	CLCS	Issuance Of Embedded Derivative Liabilities In Connection With Issuance Of Note Payable IssuanceOfEmbeddedDerivativeLiabilitiesInConnectionWithIssuanceOfNotePayable		usd
CY2022	CLCS	Issuance Of Common Stock In Connection With Extinguishment Of Note Payable IssuanceOfCommonStockInConnectionWithExtinguishmentOfNotePayable		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2023Q4	CLCS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	23624	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41019348	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023Q4	us-gaap	Cash Cash	22203	usd
CY2022Q4	us-gaap	Cash Cash	222665	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	160750	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	164175	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12218	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23005	usd
CY2023Q4	us-gaap	Assets Assets	195171	usd
CY2022Q4	us-gaap	Assets Assets	409845	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1467052	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	680325	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	960554	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	849898	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	33000	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	5217	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13043740	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39830802	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39830802	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36081758	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36081758	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	36082	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23674354	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36346176	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	409845	usd
CY2023	CLCS	Loss On Legal Settlement LossOnLegalSettlement	142600	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2604751	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2179160	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4325346	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4175333	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4325346	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4175333	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	10900	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	41920	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-995866	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-992415	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5321212	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5167748	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1228685	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1157486	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6549897	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6325234	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37786410	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37786410	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34836169	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34836169	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2022	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	1802109	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-1157486	usd
CY2022	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	1219498	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	242183	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	173712	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	5372	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	74600	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5167748	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2023	CLCS	Issuance Of Series B Convertible Preferred Stock And Warrants For Cash Net IssuanceOfSeriesBConvertiblePreferredStockAndWarrantsForCashNet	799918	usd
CY2023	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	866720	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-1228685	usd
CY2023	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	1208362	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	141672	usd
CY2023	CLCS	Adjustments To Additional Paid In Capital Issuance Of Warrants In Connection With Issuance Of Notes Payable AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	1337	usd
CY2023	CLCS	Stock Issued During Issuance Of Common Stock In Connection With Extinguishment Of Note Payable StockIssuedDuringIssuanceOfCommonStockInConnectionWithExtinguishmentOfNotePayable	58080	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	40167	usd
CY2023	CLCS	Adjustments To Additional Paid In Issuance Of Warrants In Connection With Modification Of Convertible Note Payable AdjustmentsToAdditionalPaidInIssuanceOfWarrantsInConnectionWithModificationOfConvertibleNotePayable	3529	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	71464	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5321212	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-15611543	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-15611543	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5321212	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5167748	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	41920	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	10900	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-126400	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	144661	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-102355	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-324925	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-39575	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-10787	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	6083	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	786727	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	457284	usd
CY2023	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	72774	usd
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	85881	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2347891	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3138686	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	30000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	168094	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	146912	usd
CY2023	CLCS	Proceeds From Issuance Of Convertible Preferred Stock And Warrants Net ProceedsFromIssuanceOfConvertiblePreferredStockAndWarrantsNet	799918	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	279467	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27926	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2147429	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3268256	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-200462	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	129570	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	222665	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93095	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22203	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	222665	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	949	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	19898	usd
CY2023	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-1228685	usd
CY2022	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-1157486	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	1208362	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1219498	usd
CY2023	CLCS	Financing Of Directors And Officers Insurance FinancingOfDirectorsAndOfficersInsurance	321500	usd
CY2023	CLCS	Conversion Of Series C Convertible Preferred Stock Into Common Stock ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock	753	usd
CY2023	CLCS	Conversion Of Accrued Expenses Into Note Principal ConversionOfAccruedExpensesIntoNotePrincipal	413018	usd
CY2023	CLCS	Accrual Of Warrant Obligations In Connection With Issuance Of Notes Payable AccrualOfWarrantObligationsInConnectionWithIssuanceOfNotesPayable	40167	usd
CY2023	CLCS	Warrants Issued In Satisfaction Of Accrued Warrant Obligation WarrantsIssuedInSatisfactionOfAccruedWarrantObligation	-40167	usd
CY2023	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	143009	usd
CY2022	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	242183	usd
CY2022	CLCS	Issuance Of Warrants In Satisfaction Of Accrued Interest IssuanceOfWarrantsInSatisfactionOfAccruedInterest	173712	usd
CY2023	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock	866720	usd
CY2022	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock	1802109	usd
CY2023	CLCS	Issuance Of Embedded Derivative Liabilities In Connection With Issuance Of Note Payable IssuanceOfEmbeddedDerivativeLiabilitiesInConnectionWithIssuanceOfNotePayable	12500	usd
CY2023	CLCS	Issuance Of Common Stock In Connection With Extinguishment Of Note Payable IssuanceOfCommonStockInConnectionWithExtinguishmentOfNotePayable	58080	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5321212	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5167748	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2347891	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3138686	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-15611543	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41667388	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	127963	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	128165	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zAmlC02KzZda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. Management bases its estimates and judgements on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value of the Company’s common stock price using the Backsolve method. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of any material revisions are reflected in the consolidated financial statements in the period that they are determined to be necessary. See the <i>Valuation of Common Stock Price</i> section of this note for additional detail of the use of estimates in estimating the fair value of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	19898	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	55565123	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41400493	shares
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.75
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.75
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	463650	usd
CY2022	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Warrant Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation	173712	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	173712	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	100270	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	563920	usd
CY2023	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Warrant Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation	40167	usd
CY2023	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Common Stock Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfCommonStockObligation	37959	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	40167	usd
CY2023	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issuance Of Warrants And Conversion Option FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption	43900	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-159167	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	486612	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	88644	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	86216	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	77429	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	90774	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	282330	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	254736	usd
CY2023Q4	CLCS	Accrued Severance Current AccruedSeveranceCurrent	182140	usd
CY2022Q4	CLCS	Accrued Severance Current AccruedSeveranceCurrent	164640	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	132615	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	50983	usd
CY2023Q4	CLCS	Accrued Social Security Current AccruedSocialSecurityCurrent	51986	usd
CY2022Q4	CLCS	Accrued Social Security Current AccruedSocialSecurityCurrent	77266	usd
CY2023Q4	CLCS	Stockbased Compensation Warrants StockbasedCompensationWarrants	6328	usd
CY2022Q4	CLCS	Stockbased Compensation Warrants StockbasedCompensationWarrants	8237	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	960554	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	849898	usd
CY2023	CLCS	Repayment Of Advances Payable RepaymentOfAdvancesPayable	0	usd
CY2022	CLCS	Repayment Of Advances Payable RepaymentOfAdvancesPayable	0	usd
CY2023Q4	CLCS	Issuance Of Embedded Derivative Liabilities In Connection With Issuance Of Note Payable IssuanceOfEmbeddedDerivativeLiabilitiesInConnectionWithIssuanceOfNotePayable	12500	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	247500	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	36870	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14326	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4704333	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4444646	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-616879	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-723102	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5321212	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5167748	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-853959	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-669697	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-70906	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	303995	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-554250	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-388958	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1479115	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-754660	usd
CY2023	CLCS	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	-1479115	usd
CY2022	CLCS	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	-754660	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.115	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.112	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.003	pure
CY2023	CLCS	Effective Income Tax Rate Reconciliation Permanent Differences Change In Fair Value EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFairValue	0.039	pure
CY2022	CLCS	Effective Income Tax Rate Reconciliation Permanent Differences Change In Fair Value EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFairValue	0.047	pure
CY2023	CLCS	Effective Income Tax Rate Reconciliation Prior Period True Up Other EffectiveIncomeTaxRateReconciliationPriorPeriodTrueUpOther	0.010	pure
CY2022	CLCS	Effective Income Tax Rate Reconciliation Prior Period True Up Other EffectiveIncomeTaxRateReconciliationPriorPeriodTrueUpOther	0.132	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.278	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.146	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9997830	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9071868	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	604164	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	589959	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	208283	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	939744	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	609079	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11750021	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10270906	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11750021	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10270906	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	20200000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17800000	usd
CY2023Q4	CLCS	Operating Loss Carryforwards Subject To Expiration OperatingLossCarryforwardsSubjectToExpiration	4000000	usd
CY2023Q4	CLCS	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	16200000	usd
CY2022Q4	CLCS	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	13800000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1479000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	755000	usd
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	one
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.75
CY2023	CLCS	Issuance Of Series B Convertible Preferred Stock And Warrants For Cash Net IssuanceOfSeriesBConvertiblePreferredStockAndWarrantsForCashNet	799918	usd
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	315915	usd
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	251511	usd
CY2023Q4	CLCS	Common Stock Accrued Dividend Issued CommonStockAccruedDividendIssued	403250	shares
CY2022Q4	CLCS	Common Stock Accrued Dividend Issued CommonStockAccruedDividendIssued	417944	shares
CY2023Q4	CLCS	Additional Accrued Dividend Par Value AdditionalAccruedDividendParValue	0.75
CY2022Q4	CLCS	Additional Accrued Dividend Par Value AdditionalAccruedDividendParValue	0.75
CY2023	CLCS	Accrued Dividend Designation AccruedDividendDesignation	302386	usd
CY2022	CLCS	Accrued Dividend Designation AccruedDividendDesignation	313523	usd
CY2023Q4	CLCS	Accrued Dividend Payable AccruedDividendPayable	18745	usd
CY2022Q4	CLCS	Accrued Dividend Payable AccruedDividendPayable	5217	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	463034	usd
CY2023	CLCS	Accrued Compensation AccruedCompensation	-700	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	77887	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	31346	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P0Y3M3D
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	180000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2023Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	31400	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1728028	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	2820000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	13878079	shares
CY2022Q4	CLCS	Share Based Compensation Arrangements By Share Based Payment Award Non Options Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceOutstanding	1.06
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	3838028	shares
CY2023	CLCS	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	1.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	2277500	shares
CY2023	CLCS	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expired Cacelled Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredCacelledWeightedAverageExercisePrice	0.75
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	15438607	shares
CY2023Q4	CLCS	Share Based Compensation Arrangements By Share Based Payment Award Non Options Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceOutstanding	1.09
CY2023	CLCS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P2Y10M24D
CY2023Q4	CLCS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	15218607	shares
CY2023Q4	CLCS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	1.09
CY2023	CLCS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P2Y10M24D
CY2022Q3	CLCS	Stock Options To Purchase Common Stock StockOptionsToPurchaseCommonStock	750000	shares
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2022Q3	CLCS	Fair Value Of Option FairValueOfOption	74600	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.10
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6932004	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.83
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6932004	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.83
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6932004	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.83
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2019Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	267680	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	146912	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	38838	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	113000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	360000	shares

Files In Submission

Name	View Source	Status
0001493152-24-024903-index-headers.html	Edgar Link	pending
0001493152-24-024903-index.html	Edgar Link	pending
0001493152-24-024903.txt	Edgar Link	pending
0001493152-24-024903-xbrl.zip	Edgar Link	pending
clcs-20231231.xsd	Edgar Link	pending
clcs-20231231_cal.xml	Edgar Link	unprocessable
ex10-69.htm	Edgar Link	pending
ex10-70.htm	Edgar Link	pending
ex10-71.htm	Edgar Link	pending
ex10-72.htm	Edgar Link	pending
ex10-73.htm	Edgar Link	pending
ex10-74.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clcs-20231231_def.xml	Edgar Link	unprocessable
clcs-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clcs-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLCS
Cell Source, Inc. Stock $clcs

2024 Q2 Form 10-K Financial Statement

#000149315224024903 Filed on June 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS Cell Source, Inc. Stock $clcs

2024 Q2 Form 10-K Financial Statement

#000149315224024903 Filed on June 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS
Cell Source, Inc. Stock $clcs